Novel Mechanisms of Progesterone Antagonists and Progesterone Receptor

Abstract

The progesterone receptor (PR), as a member of the nuclear receptor superfamily of ligand-dependent transcription factors, activates gene transcription through binding to specific palindromic progesterone response elements (PRE) in the promoter region of progestin-responsive genes. The progesterone antagonists ZK98299 (Onapristone) and RU 486 (Mifepristone) inhibit the transcriptional activity of PR by complex mechanisms at concentrations much lower than the progestins. Altered conformation is central to antagonist inhibition of the transcriptional activity of PR. Antagonists also promote inappropriate association of PR with corepressors. We speculate that the different PR conformations induced by agonist and antagonists results in an asymmetric agonist/antagonist heterodimer that binds inefficiently to palindromic PREs. PR, under the same cellular conditions but with different promotor contexts, can repress (β-casein) or enhance (3β-HSD) signal transducer and activator of transcription (Stat5)-mediated gene activation. The β-casein promoter appears to contain a composite DNA-binding element for PR and Stat5 and that occupancy by PR in response to progestins or antagonists suppresses Stat5 transactivation function.

Keywords

Progesterone antagonist progesterone receptor corepressor β-casein Stat5

Get full access to this article

View all access options for this article.

References

Gass E

Leonhardt S

Altmann M

, et al. The antagonists RU 486 and ZK98299 stimulate progesterone receptor binding to DNA in vitro and in vivo but have distinct effects on receptor confromation. Endocrinology1998;139:1905-1919.

Allan GF

Tsai SY

Weigel NL

, et al. Hormone and antihormone induce distinct conformation changes which are central to steroid receptor activation. J Biol Chem1992;267:19513-19520.

Weigel NL

Beck CA

Estes PA

, et al. Ligands induce confromational changes in teh carboxyl-terminus of progesterone receptors which are detected by a site-directed monoclonal antibody. Mol Endocrinol1992;6:1585-1597.

Beck CA

Zhang Y

Weigel N

, et al. Two types of anti-progestins have distinct effects on site-specific phosphorylation of human progesterone receptor. J Biol Chem1996;271:1209-1217.

Edwards DP

. Coregulatory proteins in nuclear hormone receptor action. Vitamins and Hormones1999;55:165-218.

Wagner BL

Norris JD

Knotts TA

Weigel NL

McDonnell DP

. The Nuclear Corepressors NCoR and SMRT are key regulators of both ligand- and 8-Bromo-Cyclic AMP-dependent transcriptional activity of the human progesterone receptor. Mol Cell Biol1998;18:1369-1378.

Jackson TA

Richer JK

David L. Bain

, et al. The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT. Mol Endocrinol1997;11:693-705.

Leonhardt SA

Altmann M

Edwards DP

. Agonist and antagonist induced homodimerization and mixed ligand heterdimerization of progesterone receptor in vivo by a mammalian two hybrid assay. Mol Endocrinol1998;12:1914-1930.

Gass EK

Lee CH

Anderson SM

, et al. Progesterone inhibition of β-caseini expression involves PR and Stat 5 interactions. Endocrine Society, Abstract P2-21, 1998;258-9-9.